期刊文献+

HE4和CA125联合检测在子宫内膜病变中的价值 被引量:2

Value of human epididymis secretory protein 4 combined with carbohydrate antigen125 in diagnosis of endometrial lesions
下载PDF
导出
摘要 目的探讨人附睾上皮分泌蛋白4(HE4)对子宫内膜癌的诊断意义,及其与糖链抗原125(CA125)联合检测对子宫内膜恶性肿瘤与子宫内膜良性病变的诊断价值。方法分别应用电化学发光法和双抗体夹心时间分辨免疫荧光分析法检测26例子宫内膜癌患者、28例功能失调性子宫出血患者及32例健康女性血清中的HE4和CA125水平,并进行分析。结果子宫内膜癌组的HE4水平明显高于功能失调性子宫出血组和健康对照组,差异均具有统计学意义(t值分别为2.463、2.471,均P<0.05);子宫内膜癌组中,单独检测HE4的灵敏度和特异度分别为46.27%和95.08%,单独检测CA125的灵敏度和特异度分别为39.91%和98.21%,二者联合检测时灵敏度和特异度分别为52.73%和95.03%,较CA125和HE4单项检测灵敏度增高,特异度较CA125略低。结论联合检测HE4和CA125提高了检测灵敏度,特异度降低,对子宫内膜癌具有更高的诊断价值,为联合检测HE4和CA125鉴别子宫内膜良、恶性肿瘤提供临床依据。 Objective To explore the diagnostic value of human epididymis secretory protein 4 ( HE4) in endometrial malignant tumor and to compare it with carbohydrate antigen 125 ( CA125 ) in diagnosis of endometrial malignant tumor and endometrial benign lesions. Methods Serum levels of HE4 and CA125 in 26 cases of endometrial carcinoma, 28 cases of dysfunctional uterine bleeding, and 32 cases of healthy controls were detected with electrochemiluminescence immunoassay and double antibody sandwich time-resolved immunofluorescence analysis method.Results Serum levels of HE4 among endometrial cancer patients were obviously higher than those of patients with dysfunctional uterine bleeding and healthy controls, and the differences were significant ( t value was 2.463 and 2.471, respectively, both P〈0.05).In endometrial cancer group, the sensitivity and specificity of detection of HE4 were 46.27%and 95.08%, respectively, and those of CA125 were 39.91%and 98.21%, respectively.The sensitivity of joint detection (52.73%) was higher than that of HE4 and CA125, but the specificity of joint detection (95.03%) was lower than that of CA125.Conclusion Joint detection of HE4 and CA125 improves the sensitivity but reduces the specificity, which has higher diagnostic value for endometrial cancer.It provides clinical evidence for differential diagnosis of endometrial benign from malignant tumors.
出处 《中国妇幼健康研究》 2015年第4期709-711,714,共4页 Chinese Journal of Woman and Child Health Research
关键词 子宫内膜恶性肿瘤 子宫内膜良性病变 人附睾上皮分泌蛋白4 糖链抗原125 endometrial malignant tumor endometrial benign lesions human epididymis secretory protein 4 ( HE4 ) carbohydrate antigen125 (CA125)
  • 相关文献

参考文献13

  • 1谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013:118-119. 被引量:1253
  • 2Li Jin-ping, Dowdy Sean, Tipton T, et al. HFA as a biomarker for ovarian and endometrial cancer management [ J 1. Expert Rev Mol Diagn ,2009,9(6) :555-566. 被引量:1
  • 3Chen Y L, Huang C Y, Chien T Y, et al. Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer [ J 1. Aust N Z J Obstet Gynaecol, 2011,51 ( 5 ) : 397-402. 被引量:1
  • 4Escudero J M, Auge J M, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant disease[ J]. Clin Chem, 2011,57 ( 11 ) : 1534-1544. 被引量:1
  • 5Moore R G, Brown A K, Miller M C, et al. Utility of a novel serum tumor biomarker HFA in patients with endometrioid adenocarcinoma of the uterus J. Gynecol Oncol, 2008, 110(2) :196-201. 被引量:1
  • 6Montagnana M, Lippi G, Ruzzenente O, et al. The utility of serum human epididymis protein 4 (HFA) in patients with a pelvic mass [ J 1. J Clin Lab Anal,2009,23 ( 5 ) : 331-335. 被引量:1
  • 7Huhtinen K, Suvitie P, Hiissa J, et al. Serum HFA concentration differentiates malignant ovarian turnouts from ovarian endometriotic cysts[Jl. Br J Cancer, 2009, 100(8) : 1315-1319. 被引量:1
  • 8Li Jin-ping, Chen Hai-bin, Mariani A , et al. HFA ( WFDC2 ) promotes tumor growth in endometrial cancer cell lines L Jl. Int J Mol Sci,2013,14 ( 3 ) : 602645043. 被引量:1
  • 9Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patiensl J]. Br J Cancer, 2011, 104(9): 1418-1425. 被引量:1
  • 10Moore R G, McMeekin D S, Brown A K, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass [ J ]. Gynecol Oncol,2009,112 ( 1 ) :40-46. 被引量:1

二级参考文献8

  • 1Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother,2004,58 : 24 -38. 被引量:1
  • 2Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer,2000,82 : 1535-1538. 被引量:1
  • 3Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003,63 : 3695 -3700. 被引量:1
  • 4Israeli O, Goldring-Aviram A, Rienstein S, et al. In sihco chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet,2005 ,160 :35- 42. 被引量:1
  • 5Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 ( HE4 ) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005, 65:2162-2169. 被引量:1
  • 6Kirchhoff C, Habben I, Ivell R, et al. A major human epididymisspecific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod, 1991,45: 350- 357. 被引量:1
  • 7Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol,2008,108:402-408. 被引量:1
  • 8刘润幸.使用SPSS作多变量观察值的ROC曲线分析[J].中国公共卫生,2003,19(9):1151-1152. 被引量:128

共引文献1349

同被引文献19

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部